Regeneron Pharmaceuticals, Inc. (BVL:REGNUS)
Peru · Delayed Price · Currency is PEN · Price in USD | Market Cap | 259.09B +24.0% |
| Revenue (ttm) | 53.05B +9.3% |
| Net Income | 14.78B -2.9% |
| EPS | 138.07 +1.9% |
| Shares Out | n/a |
| PE Ratio | 17.53 |
| Forward PE | 11.43 |
| Dividend | 12.72 (0.56%) |
| Ex-Dividend Date | May 20, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 667.17 |
| Day's Range | n/a |
| 52-Week Range | 565.20 - 751.57 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron price target raised to $737 from $696 at RBC Capital
RBC Capital raised the firm’s price target on Regeneron (REGN) to $737 from $696 and keeps a Sector Perform rating on the shares. The company reported strong sales across the…
Regeneron price target raised to $758 from $730 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Regeneron (REGN) to $758 from $730 and keeps an Equal Weight rating on the shares after “a solid 2Q beat on both…
Regeneron price target raised to $891 from $856 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Regeneron (REGN) to $891 from $856 and keeps a Buy rating on the shares. Dupixent’s beat in Q2 raises the…
Regeneron price target raised to $795 from $750 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Regeneron (REGN) to $795 from $750 and keeps an Overweight rating on the shares. Regeneron’s Q2 results reduced near-term…
Regeneron price target raised to $761 from $742 at Baird
Baird raised the firm’s price target on Regeneron (REGN) to $761 from $742 and keeps a Neutral rating on the shares. The firm updated its model following impressive Q2 results…
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026 ...
Regeneron price target raised to $750 from $700 at Wells Fargo
Wells Fargo raised the firm’s price target on Regeneron (REGN) to $750 from $700 and keeps an Equal Weight rating on the shares. The firm believes the company’s Q2 reinforces…
Regeneron Pharmaceuticals Earnings Call Transcript: Q2 2026
Second quarter revenue rose 17% year-over-year to $4.3B, with double-digit EPS growth and record sales for Dupixent, EYLEA HD, and Libtayo. The pipeline remains robust with multiple regulatory milestones ahead, and capital allocation continues to prioritize internal R&D and disciplined external opportunities.
Regeneron Pharmaceuticals Earnings release: Q2 2026
Regeneron Pharmaceuticals released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Regeneron Pharmaceuticals Quarterly report: Q2 2026
Regeneron Pharmaceuticals has published its Q2 2026 quarterly earnings report on July 30, 2026.
Regeneron Pharmaceuticals Slides: Q2 2026
Regeneron Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Regeneron cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
08:17 EDT Regeneron (REGN) cuts FY26 CapEx view to $1.03B-$1.1B from $1.1B-$1.2B
Regeneron beats quarterly estimates on eczema drug strength, shares rise
Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.
Regeneron reports Q2 adjusted EPS $14.29, consensus $10.20
Reports Q2 revenue $4.3B, consensus $3.83B. “Regeneron (REGN) delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength...
Regeneron Reports Second Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2026 and provided a business update.
REGN Stockholders Have Rights – If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceut...
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
At Regeneron, George Yancopoulos is the rare scientist and executive who drives growth with discoveries instead of acquisitions.
$REGN Fraud Notification: Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FD...
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
NEW YORK--(BUSINESS WIRE)---- $REGN #BFA--Regeneron Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA.
Regeneron price target raised to $1,000 from $995 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Regeneron (REGN) to $1,000 from $995 and keeps a Buy rating on the shares. The firm is revising some of…
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Biohaven enters into clinical supply agreement with Regeneron
Biohaven (BHVN) has entered into a clinical supply agreement with Regeneron Pharmaceuticals (REGN) to evaluate the combination of BHV-1530 and cemiplimab, or Libtayo, in patients with solid tumors bas...
Booking, Alphabet, and 7 Other Stocks to Buy Ahead of Earnings
Booking Holdings, Alphabet, and six other companies have underperformed their sectors despite improving earnings expectations, setting up potential upside during second-quarter earnings season.
Regeneron’s dupilumab granted orphan drug designation
Regeneron’s (REGN) dupilumab was granted FDA orphan drug designation, according to a post on the agency’s website.